

Roxana Mehran, Mscai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5050958/publications.pdf>

Version: 2024-02-01

303
papers

54,576
citations

5782

84
h-index

1371

228
g-index

306
all docs

306
docs citations

306
times ranked

27495
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
2	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
3	A Prospective Natural-History Study of Coronary Atherosclerosis. <i>New England Journal of Medicine</i> , 2011, 364, 226-235.	13.9	2,721
4	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
5	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
6	Bivalirudin during Primary PCI in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2218-2230.	13.9	1,693
7	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S45-S60.	0.6	1,605
8	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1438-1454.	1.2	1,560
9	Bivalirudin for Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 355, 2203-2216.	13.9	1,367
10	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016, 375, 2423-2434.	13.9	1,265
11	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	1.2	1,232
12	A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1393-1399.	1.2	1,127
13	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACCP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016, 134, e123-55.	1.6	1,069
14	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>European Heart Journal</i> , 2012, 33, 2403-2418.	1.0	900
15	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2223-2235.	13.9	843
16	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
17	Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1362-1368.	1.2	776
18	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet</i> , The, 2013, 382, 614-623.	6.3	740

#	ARTICLE	IF	CITATIONS
19	Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2011, 57, 253-269.	1.2	735
20	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	13.9	683
21	The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1542-1548.	1.2	669
22	In-Stent Restenosis in the Drug-Eluting Stent Era. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1897-1907.	1.2	663
23	Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 1946-1959.	13.9	657
24	A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2556-2566.	1.2	590
25	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2022, 79, e21-e129.	1.2	561
26	Complete Revascularization with Multivessel PCI for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 1411-1421.	13.9	542
27	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013, 382, 1714-1722.	6.3	537
28	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021, 397, 2385-2438.	6.3	530
29	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1820-1830.	13.9	523
30	Consideration of a New Definition of Clinically Relevant Myocardial Infarction After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1563-1570.	1.2	506
31	Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1397-1405.	1.2	451
32	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	1.2	445
33	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
34	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. <i>European Heart Journal</i> , 2020, 41, 3504-3520.	1.0	385
35	Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2002, 39, 591-597.	1.2	370
36	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368

#	ARTICLE	IF	CITATIONS
37	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet</i> , The, 2007, 369, 907-919.	6.3	367
38	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366
39	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	13.9	362
40	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1036-1045.	1.2	344
41	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1845-1854.	1.2	343
42	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. <i>European Heart Journal</i> , 2021, 42, 1825-1857.	1.0	342
43	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
44	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 654-664.	1.1	329
45	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.	1.0	315
46	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1298-1310.	1.2	314
47	Characterization of Myocardial Injury in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2043-2055.	1.2	303
48	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
49	Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2004, 44, 547-553.	1.2	238
50	Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: Study design and rationale. <i>American Heart Journal</i> , 2004, 148, 764-775.	1.2	231
51	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 191-197.	1.1	229
52	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 857-867.	1.1	223
53	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. <i>Circulation</i> , 2001, 104, 642-647.	1.6	207
54	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	13.9	207

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	3.0	198
56	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 130-139.	13.9	194
57	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
58	Standardized End Point Definitions for Coronary Intervention Trials. <i>European Heart Journal</i> , 2018, 39, 2192-2207.	1.0	179
59	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, CIR0000000000001038.	1.6	177
60	Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. <i>Circulation</i> , 2005, 111, 1611-1618.	1.6	173
61	Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2733-2744.	1.2	160
62	The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. <i>American Heart Journal</i> , 2008, 156, 44-56.	1.2	152
63	Antithrombotic Treatment in Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2349-2359.	1.2	151
64	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002475.	1.4	148
65	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1918-1930.	1.6	148
66	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 373, n1332.	3.0	144
67	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. <i>New England Journal of Medicine</i> , 2021, 385, 2150-2160.	13.9	144
68	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). <i>American Heart Journal</i> , 2015, 169, 472-478.e5.	1.2	140
69	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2711-2722.	1.2	139
70	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500.	1.6	132
71	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	6.3	127
72	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	1.2	126

#	ARTICLE	IF	CITATIONS
73	Predictors of Infarct Size After Primary Coronary Angioplasty in Acute Myocardial Infarction from Pooled Analysis from Four Contemporary Trials. <i>American Journal of Cardiology</i> , 2007, 100, 1370-1375.	0.7	125
74	Ticagrelor With or Without Aspirin After ComplexÂPCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	1.2	122
75	Drug-Eluting Stent for Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 718-727.	1.1	121
76	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
77	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2860-2868.	1.2	116
78	Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial. <i>American Heart Journal</i> , 2006, 151, 1231-1238.	1.2	111
79	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	1.2	108
80	Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. <i>Journal of Invasive Cardiology</i> , 2003, 15, 18-22.	0.4	103
81	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1097-1105.	1.1	101
82	Contrastâ€induced nephropathy. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 62-72.	0.7	99
83	Coronary Plaque Composition, Morphology, and Outcomes in Patients With and Without Chronic Kidney Disease Presenting With Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S53-S61.	2.3	93
84	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	1.0	93
85	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	1.0	92
86	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2021, 42, 308-319.	1.0	90
87	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
88	Impact and Determinants of Left Ventricular Function in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2005, 96, 325-331.	0.7	85
89	Acute and 30-Day Outcomes in WomenÂAfter TAVR. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1589-1600.	1.1	85
90	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84

#	ARTICLE	IF	CITATIONS
91	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
92	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1-12.	1.1	77
93	Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. <i>European Heart Journal</i> , 2019, 40, 1334-1340.	1.0	77
94	Coronary In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2022, 80, 348-372.	1.2	72
95	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. <i>International Journal of Cardiology</i> , 2017, 231, 61-67.	0.8	71
96	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	3.0	71
97	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	6.1	71
98	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
99	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	1.2	69
100	Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 859-866.	0.7	69
101	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. <i>Lancet</i> , The, 2021, 398, 1974-1983.	6.3	69
102	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	1.2	66
103	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001683.	1.4	65
104	5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 300-309.	1.1	64
105	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	63
106	Ionic Low-Osmolar Versus Nonionic Iso-Osmolar Contrast Media to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 415-421.	1.1	62
107	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 268-277.	1.1	62
108	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	1.2	60

#	ARTICLE	IF	CITATIONS
109	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 3341-3350.	1.0	59
110	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 754-765.	1.2	59
111	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1846-1857.	1.2	58
112	Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEichâ€™s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. <i>European Heart Journal</i> , 2018, 39, 2460-2468.	1.0	58
113	Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. <i>Journal of the American College of Cardiology</i> , 2000, 35, 944-948.	1.2	57
114	Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 3440-3447.	1.0	57
115	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
116	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021, 42, 339-351.	1.0	57
117	Sexâ€™related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 629-637.	0.7	56
118	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1870-1883.	1.1	56
119	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007411.	1.4	55
120	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 375-387.	1.1	55
121	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357.	1.1	54
122	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634.	1.0	54
123	Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). <i>American Journal of Cardiology</i> , 2014, 114, 1823-1829.	0.7	53
124	Safety and Efficacy of Double Antithrombotic Therapy With Nonâ€™Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Metaâ€™Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e017212.	1.6	52
125	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. <i>JAMA Cardiology</i> , 2021, 6, 410.	3.0	52
126	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	1.1	51

#	ARTICLE	IF	CITATIONS
127	Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training. JACC: Cardiovascular Interventions, 2019, 12, 219-228.	1.1	49
128	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circulation: Cardiovascular Interventions, 2020, 13, e009565.	1.4	49
129	High Platelet Reactivity on Clopidogrel Therapy Correlates With Increased Coronary Atherosclerosis and Calcification. JACC: Cardiovascular Imaging, 2012, 5, 540-549.	2.3	48
130	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	46
131	Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation. JAMA Cardiology, 2017, 2, 1303.	3.0	46
132	Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality. JACC: Cardiovascular Interventions, 2013, 6, 718-724.	1.1	42
133	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nature Reviews Cardiology, 2021, 18, 37-57.	6.1	42
134	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 97, 1387-1396.	0.7	42
135	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	1.1	41
136	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. American Heart Journal, 2016, 171, 40-47.	1.2	40
137	Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Are Associated With Adverse Outcomes. Journal of the American College of Cardiology, 2012, 59, 1745-1751.	1.2	39
138	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing) Tj ETQq0 0 0 rgBT /Overlock 10 T of Cardiology, 2017, 119, 1710-1716.	0.7	39
139	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	1.2	39
140	Influence of gender on early and one-year clinical outcomes after saphenous vein graft stenting. American Journal of Cardiology, 2001, 87, 401-405.	0.7	38
141	Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the) Tj ETQq1 1 0.784314 rgBT /Overlock American Journal of Cardiology, 2014, 114, 9-16.	0.7	38
142	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	38
143	Impact of calcification on percutaneous coronary intervention: MACEâ€“Trial 1â€“year results. Catheterization and Cardiovascular Interventions, 2019, 94, 187-194.	0.7	36
144	Gender differences in outcomes in patients with acute coronary syndrome in the current era: A review. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 51-60.	0.4	35

#	ARTICLE	IF	CITATIONS
145	Percutaneous Coronary Intervention of Saphenous Vein Graft. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	35
146	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	0.7	35
147	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	1.2	35
148	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
149	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. <i>Nature Reviews Cardiology</i> , 2022, 19, 195-208.	6.1	34
150	The Academic Research Consortium Governance Charter. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 595-596.	1.1	33
151	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. <i>International Journal of Cardiology</i> , 2018, 250, 66-72.	0.8	33
152	Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.7	32
153	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 43</i> Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
154	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	1.1	32
155	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
156	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1-month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	1.2	31
157	In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. <i>American Journal of Cardiology</i> , 1999, 84, 1381-1384.	0.7	30
158	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. <i>American Journal of Cardiology</i> , 2014, 114, 1339-1346.	0.7	30
159	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	6.1	30
160	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). <i>American Journal of Cardiology</i> , 2015, 116, 37-42.	0.7	28
161	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28
162	Types of myocardial injury and mid-term outcomes in patients with COVID-19. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 438-446.	1.8	28

#	ARTICLE	IF	CITATIONS
163	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
164	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	1.1	27
165	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	1.2	25
166	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	3.0	25
167	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 626-634.	1.1	25
168	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019, 208, 81-90.	1.2	25
169	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. <i>Journal of the American College of Cardiology</i> , 2022, 80, 63-88.	1.2	25
170	Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1186-1193.	1.2	24
171	Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. <i>American Journal of Cardiology</i> , 2004, 93, 963-968.	0.7	23
172	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018897.	1.6	23
173	<sc>SCAI</sc> expert consensus statement on out of hospital cardiac arrest. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 844-861.	0.7	23
174	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	1.6	23
175	Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. <i>Cardiovascular Research</i> , 2023, 119, 631-646.	1.8	23
176	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 428-433.	0.7	22
177	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	0.7	22
178	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 492-502.	1.4	22
179	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. <i>EuroIntervention</i> , 2014, 10, 312-319.	1.4	22
180	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1969-1978.	1.1	21

#	ARTICLE	IF	CITATIONS
181	Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy. <i>JAMA Cardiology</i> , 2020, 5, 939.	3.0	21
182	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	1.4	21
183	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1277-1286.	1.2	20
184	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 557-567.	1.4	20
185	Comparison of Bivalirudin Versus Bivalirudin Plus Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Having Percutaneous Intervention for Narrowed Saphenous Vein Aorto-Coronary Grafts (the ACUITY Trial Investigators). <i>American Journal of Cardiology</i> , 2010, 106, 941-945.	0.7	19
186	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	0.7	19
187	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. <i>International Journal of Cardiology</i> , 2019, 283, 67-72.	0.8	19
188	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1494-1500.	0.7	19
189	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , 2016, 117, 1703-1713.	0.7	18
190	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	0.7	18
191	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	1.0	18
192	Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006853.	1.4	17
193	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing transcatheter aortic valve implantation for severe aortic stenosis: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 516-526.	0.7	17
194	Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes of Treatment of Bifurcation Lesions Study). <i>EuroIntervention</i> , 2013, 9, 817-823.	1.4	17
195	The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: A subanalysis of the BRAVO study. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 148-153.	0.7	16
196	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2016, 117, 192-200.	0.7	16
197	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>International Journal of Cardiology</i> , 2017, 246, 20-25.	0.8	15
198	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	14

#	ARTICLE	IF	CITATIONS
199	Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: An analysis of Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI). <i>American Heart Journal</i> , 2015, 169, 86-93.	1.2	13
200	Bleeding Severity After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005542.	1.4	13
201	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020, 120, 348-362.	1.8	13
202	Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 1241-1249.	0.7	13
203	Patients with COVID-19 who experience a myocardial infarction have complex coronary morphology and high in-hospital mortality: Primary results of a nationwide angiographic study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E370-E378.	0.7	13
204	Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. <i>EuroIntervention</i> , 2009, 5, 417-424.	1.4	13
205	Evidence base for the management of women with non-ST elevation acute coronary syndrome. <i>Heart</i> , 2022, 108, 1682-1689.	1.2	13
206	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 1166-1172.	0.7	12
207	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014611.	1.6	12
208	Gender-specific outcomes after balloon aortic valvuloplasty: In-hospital and long-term outcomes. <i>American Heart Journal</i> , 2015, 170, 180-186.	1.2	11
209	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	0.8	11
210	Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 298-308.	0.7	11
211	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	1.4	11
212	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1968-1986.	1.2	11
213	Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 563-569.	1.4	10
214	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) <i>TJ ETQq0 0 0 rgBT /Overlock 10</i> 2017, 120, 904-910.	0.7	10
215	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. <i>International Journal of Cardiology</i> , 2019, 297, 22-29.	0.8	10
216	Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 82-90.	0.7	10

#	ARTICLE	IF	CITATIONS
217	The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2019, 17, 151-159.	0.6	10
218	1-Year Clinical Outcomes of All-Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2020, 13, 820-830.	1.1	10
219	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. American Journal of Cardiology, 2016, 118, 6-16.	0.7	9
220	Women's Voices in Cardiology. JAMA Cardiology, 2018, 3, 676.	3.0	9
221	Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: Analysis from the HORIZONS-AMI trial. Catheterization and Cardiovascular Interventions, 2019, 94, 172-180.	0.7	9
222	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	0.7	9
223	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2020, 125, 441-448.	0.7	9
224	Treating Inflammation Prior to Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009127.	1.4	9
225	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2021, 143, 1215-1223.	1.6	9
226	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	0.8	8
227	Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Critical Pathways in Cardiology, 2020, 19, 69-74.	0.2	8
228	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	0.7	8
229	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2022, 53, 20-29.	1.0	8
230	Outcomes After Successful Percutaneous Coronary Intervention of Calcified Lesions Using Rotational Atherectomy, Cutting-Balloon Angioplasty, or Balloon-Only Angioplasty Before Drug-Eluting Stent Implantation. Journal of Invasive Cardiology, 2017, 29, 378-386.	0.4	8
231	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1788-1795.	0.7	7
232	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. American Heart Journal, 2019, 207, 10-18.	1.2	7
233	Cardiovascular outcomes after percutaneous coronary intervention on bifurcation lesions with moderate to severe coronary calcium: A single-center registry study. Catheterization and Cardiovascular Interventions, 2020, 98, 35-42.	0.7	7
234	Temporal Trends in the Proportion of Women Physician Speakers at Major Cardiovascular Conferences. Circulation, 2021, 143, 755-757.	1.6	7

#	ARTICLE	IF	CITATIONS
235	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	0.7	7
236	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 697</i>		
237	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , 2016, 118, 1661-1668.	0.7	6
238	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	1.4	6
239	Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 558-564.	0.7	6
240	Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2882-2892.	1.1	6
241	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI : TWILIGHT-SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	0.7	6
242	Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010392.	1.4	6
243	Atrial fibrillation, with ACS and PCI: walking a tightrope. <i>European Heart Journal</i> , 2019, 40, 1563-1566.	1.0	5
244	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 42-51.	1.0	5
245	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E377-E386.	0.7	5
246	Comparison of One-Year Outcomes in Patients >75 Versus <75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). <i>American Journal of Cardiology</i> , 2020, 127, 1-8.	0.7	5
247	One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1341-1351.	0.7	5
248	Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus. <i>Future Cardiology</i> , 2020, 16, 613-623.	0.5	5
249	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. <i>Journal of the American Heart Association</i> , 2022, 11, e022320.	1.6	5
250	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 707-716.	1.4	5
251	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. <i>EuroIntervention</i> , 2022, 17, 1330-1339.	1.4	5
252	Invasive Versus Medical Management in Patients With Chronic Kidney Disease and Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2022, 11,	1.6	5

#	ARTICLE	IF	CITATIONS
253	Antithrombotic strategy variability in Atrial fibrillation and obstructive coronary disease revascularized with PCI—rationale and study design of the prospective observational multicenter AVIATOR 2 registry. <i>American Heart Journal</i> , 2015, 170, 1234-1242.	1.2	4
254	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 797-804.	0.7	4
255	Gender Issues in Italian Catheterization Laboratories: The Gender-CATH Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017537.	1.6	4
256	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 380-389.	1.0	4
257	Why stronger radiation safety measures are essential for the modern workforce. A perspective from EAPCI Women and Women as One. <i>EuroIntervention</i> , 2020, 16, 24-25.	1.4	4
258	Sex Differences in Cardiovascular Research: A Scientometric Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e021522.	1.6	4
259	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. <i>American Journal of Cardiology</i> , 2022, 168, 47-54.	0.7	4
260	The new European Society of Cardiology/European Association for Cardio-Thoracic Surgery recommendations for transcatheter aortic valve intervention are too restrictive. <i>European Heart Journal</i> , 2022, 43, 2751-2752.	1.0	4
261	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). <i>American Journal of Cardiology</i> , 2022, 172, 73-80.	0.7	4
262	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
263	A Biomarker-Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e025729.	1.6	4
264	Off-label use of drug-eluting stents: assessing the risk. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 594-595.	3.3	3
265	Ticagrelor Monotherapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2235-2237.	1.2	3
266	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1542-1547.	0.3	3
267	Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. <i>Future Cardiology</i> , 2021, 17, 521-534.	0.5	3
268	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following PCI: Analysis from the Onyx ONE clear study. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 583-592.	0.7	3
269	The year in cardiovascular medicine 2021: interventional cardiology. <i>European Heart Journal</i> , 2022, 43, 377-386.	1.0	3
270	Hope for the best, prepare for the worst: How to manage coronary perforations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E255-E256.	0.7	2

#	ARTICLE	IF	CITATIONS
271	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1111-1119.	0.7	2
272	Drug-eluting stents in diabetic patients: Are we still treading water?. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 253-254.	0.7	2
273	Pregnancy during cardiology training: a call to action. <i>Heart</i> , 2021, 107, 1018-1019.	1.2	2
274	One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 309-320.	1.3	2
275	Impact of anemia on short-term outcomes after TAVR : A subgroup analysis from the BRAVO randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E870-E880.	0.7	2
276	Sexual Harassment, Victim Blaming, and the Potential Impact on Women in Cardiology. <i>JACC: Case Reports</i> , 2021, 3, 978-981.	0.3	2
277	First and recurrent events in the ISCHEMIA trial: two sides of the same coin. <i>European Heart Journal</i> , 2021, , .	1.0	2
278	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
279	Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2022, 38, 792-800.	0.8	2
280	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	1.4	2
281	Elderly patients with acute myocardial infarction: Targeted or complete revascularization?. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 979-980.	0.7	2
282	Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon. <i>European Heart Journal</i> , 2022, 43, 3145-3147.	1.0	2
283	Equal sex-based outcomes in unprotected left main PCI: No advantage for men. <i>International Journal of Cardiology</i> , 2018, 253, 61-63.	0.8	1
284	Towards a standardized classification of cardiogenic shock: Will the new <scp>SCAI</scp> staging system translate into better clinical practice and research?. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1348-1349.	0.7	1
285	Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. <i>Journal of the American Heart Association</i> , 2021, 10, e019889.	1.6	1
286	Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 2710-2711.	1.0	1
287	Single antiplatelet therapy after transcatheter aortic valve implantation: clarity on existing data. <i>European Heart Journal</i> , 2021, 42, 3203-3204.	1.0	1
288	Stick to the guidelines or clinical judgment: A toss up?. <i>International Journal of Cardiology</i> , 2021, 338, 83-84.	0.8	1

#	ARTICLE	IF	CITATIONS
289	Evaluation of Cerebral Thromboembolism After Transcatheter Aortic Valve Replacement (EARTH TAVR): A Serial Magnetic Resonance Imaging Evaluation as Substudy of the GALILEO Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011074.	1.4	1
290	Readmission in Patients With ST-Elevation Myocardial Infarction in 4 Age Groups (≤ 45 to > 75 Years). <i>Circulation</i> , 2019, 140, e111-118.	6.7	1
291	The year in cardiovascular medicine 2021: interventional cardiology. <i>Cardiologia Croatica</i> , 2022, 17, 59-72.	0.0	1
292	Can manual thrombus aspiration improve myocardial reperfusion?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 68-69.	3.3	0
293	Reply. <i>American Journal of Cardiology</i> , 2017, 120, e33.	0.7	0
294	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2020, 137, 1-6.	0.7	0
295	Transcatheter aortic valve replacement in patients with \leq stage renal disease: Is it better than nothing? <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1110-1112.	0.7	0
296	Women and Cardiac Disease: A Special Issue. <i>International Journal of Cardiovascular Sciences</i> , 2021, 34, 338-339.	0.0	0
297	Interventions in Ischemic Heart Disease. , 2021, , 93-108.		0
298	Prolonged dual antiplatelet therapy in selected patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 114-115.	0.7	0
299	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
300	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization—A Powerful Reminder and Call to Action. , 2022, , 100006.		0
301	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e023143.	1.6	0
302	The Final Word: Current Strategies for the Lifetime Management of Patients with Aortic Valve Stenosis. <i>US Cardiology Review</i> , 0, 16, .	0.5	0
303	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1963-1965.	1.2	0